Researcher
MD, MSHPM
Associate Professor
Chief of the Division of Urologic Oncology
University of North Carolina at Chapel Hill
THIS PROFILE WAS GENERATED FROM PUBLICLY AVAILABLE SOURCES AND REVIEWED BY THE RESEARCHER.
A concise summary of research focus, trajectory, and current direction.
Dr. Hung-Jui (Ray) Tan is the Chief of Urologic Oncology at UNC and an Associate Professor specializing in kidney, bladder, and prostate cancer. He is a health services researcher focused on improving cancer care delivery through user-centered design, clinical informatics, and decision support tools. He holds an MD from the University of Michigan and an MSHPM from UCLA.
PRIMARY SOURCES:
https://unclineberger.org/directory/ray-tan/Ranked by current emphasis.
Cancer Care Delivery and Translation
Clinical Informatics and Decision Support Tools
Urologic Oncology (Kidney, Prostate, Bladder)
Aging and Geriatric Cancer Care
Health Policy and Comparative Effectiveness
Summarizes applied impact and ongoing priorities.
Dr. Tan bridges clinical urology with health services research, specifically developing visual and digital tools to enhance patient-centered decision-making in kidney cancer. He was recognized as the AUA Young Urologist of the Year in 2024.
Areas where collaboration may be of interests.
Based on published and institutional information.
Representative publications. Not a complete list.
Designing visual tools to enhance cancer surgeon decision-making
2024
Personalizing kidney cancer information to support patient-centered decision making
2023
Comparative Effectiveness of New Cancer Treatments in the Elderly
2022
Positions held by the researcher.
Chief, Division of Urologic Oncology
University of North Carolina at Chapel Hill
2023 - present
Associate Professor of Urology
University of North Carolina at Chapel Hill
2020 - present
Fellowship Program Director, Urologic Oncology
University of North Carolina at Chapel Hill
2021 - present
Staff Physician
Veterans Affairs West Los Angeles Medical Center
2013 - 2016
From community health to specialized clinical pathways, our platform gives teams everything they need to translate validated care methods into real-world, scalable solutions.